<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04606901</url>
  </required_header>
  <id_info>
    <org_study_id>26881</org_study_id>
    <nct_id>NCT04606901</nct_id>
  </id_info>
  <brief_title>Comparison of Time to Extubation Using Sugammadex or Neostigmine</brief_title>
  <official_title>Comparison of Time to Full Recovery From Muscle Paralysis (TOF&gt;0.9) and Extubation Using Sugammadex Versus Neostigmine/Glycopyrrolate in Patients With Pulmonary Disease in the Outpatient Bronchoscopy Suite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective blinded randomized clinical trial to compare time to extubation using&#xD;
      Sugammadex versus Neostigmine/glycopyrrolate as reversal agents after use of neuromuscular&#xD;
      blockade agents in an outpatient bronchoscopy suite.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study will have the design of a blinded randomized clinical trial. The&#xD;
      pharmacist will be blinded to the study medication given. The anesthesia provider cannot be&#xD;
      blinded because he/she will need to determine the proper dose and timing of the neuromuscular&#xD;
      blocker reversal medication (the study medications) given at the end of the procedure. The&#xD;
      study will recruit 80 patients coming to Temple University Hospital for an outpatient&#xD;
      bronchoscopy biopsy procedure that requires general anesthesia with neuromuscular blockade.&#xD;
      Rocuronium will be the neuromuscular blockade medication given in this study. Inclusion&#xD;
      criteria for these patients will include those age &gt;18 who have a diagnosis of chronic&#xD;
      obstructive pulmonary disease (COPD) and/or idiopathic lung disease (ILD) and who require&#xD;
      medical treatment for the same; these patients will have American society of anesthesiology&#xD;
      physical status (ASA PS) 3-4 based on their pulmonary disease alone.The patients will then be&#xD;
      randomly assigned to one of two study arms (40 per arm). Patients in one arm of the study&#xD;
      will receive Sugammadex and patients in the other arm will receive neostigmine/glycopyrrolate&#xD;
      for reversal of neuromuscular blockade. Due to the nature of bronchoscopy for biopsy, the&#xD;
      depth of anesthesia at the end of the case will be difficult to predict; the length of the&#xD;
      cases may vary some (although most will be approximately one hour), and patients' metabolism&#xD;
      of neuromuscular blocking agents is very much dependent on their personal medication regimens&#xD;
      and liver function. Each patient's depth of neuromuscular blockade will be followed using the&#xD;
      TwitchView monitor, a commercially available, an electromyography (EMG) based monitor. The&#xD;
      TwitchView measures muscle response to delivered electrical stimuli (2Hz) which are sent in&#xD;
      sets of 4X0.5 seconds apart (most commonly). The muscles controlled by the ulnar nerve will&#xD;
      be followed during this study. Return of muscle strength after reversal agents are given is&#xD;
      considered complete when the ratio of the strength of the response to the fourth electrical&#xD;
      stimulus to the first stimulus is 0.9. Multiple time points will be recorded, including train&#xD;
      of four measurement (TOF) every 5 minutes during the procedure, time and TOF at the end of&#xD;
      the procedure, time of reversal medication dosing, time of TOF&gt;0.9 and time of extubation.&#xD;
      Reversal medication will be given as soon as each patient's procedure is complete and the&#xD;
      patient meets appropriate criteria for reversal for each respective medication. Comparison of&#xD;
      the data from the two arms of the study will then be made.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study groups will be treated equally except for delivery of the neuromuscular blockade reversal medication</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Medications will be provided by Merck, Sharp &amp; Dohme Corp and will be delivered to the inpatient pharmacy in such a way as to blind the pharmacist. Patients will also not know which medication they are receiving</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>number of minutes to return of baseline muscle tone</measure>
    <time_frame>1-20 minutes</time_frame>
    <description>number of minutes to TOF&gt;0.9 indicating full reversal of neuromuscular blockade agent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of minutes to extubation</measure>
    <time_frame>1-30 minutes</time_frame>
    <description>number of minutes from TOF&gt;0.9 to extubation of the patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm of the study will receive Sugammadex as the drug used to reverse neuromuscular blockade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neostigmine/Glycopyrrolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm of the study will receive Neostigmine/Glycopyrrolate as the drugs used to reverse neuromuscular blockade</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine/glycopyrrolate</intervention_name>
    <description>neuromuscular blockade reversal agents</description>
    <arm_group_label>Neostigmine/Glycopyrrolate</arm_group_label>
    <other_name>prostigmin/robinul</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>neuromuscular blockade reversal agent</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. has diagnosis of COPD or ILD&#xD;
&#xD;
          2. ASA 3 or 4&#xD;
&#xD;
          3. procedure requires general anesthesia in the outpatient bronchoscopy suite&#xD;
&#xD;
          4. glomerular filtration rate &gt; 30 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnant women&#xD;
&#xD;
          2. prisoners&#xD;
&#xD;
          3. those unable to consent for themselves&#xD;
&#xD;
          4. procedures not requiring general anesthesia&#xD;
&#xD;
          5. ASA 1 or 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Hauck, DO PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lewis Katz School of Medicine at Temple University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Hauck, DO PhD</last_name>
    <phone>215-707-3326</phone>
    <email>ellen.hauck@tuhs.temple.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ellen S Hauck, DO PhD</last_name>
      <phone>215-707-3326</phone>
      <email>ellenha4@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nondepolarizing neuromuscular blockade</keyword>
  <keyword>sugammadex</keyword>
  <keyword>bronchoscopy</keyword>
  <keyword>outpatient</keyword>
  <keyword>lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only deidentified data from the study will be made available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

